Metabolic impact of switching from EFV/TDF/FTC to two INSTI-Based regimens (B/F/TAF vs. DTG/3TC): a real-world study in virologically suppressed individuals

Read full text Summarise with VIRAT
Authors: Er Li, Yu Wang, Dingyan Yan, Jinchuan Shi, Jianhua Yu, Xiaowei Hu, Wenhui Zhang
Cited by: 0
References: 40

Summary

No summary yet. VIRAT can read this paper and write a plain-language summary of its aim, methods, key findings and limitations.

Summarise with VIRAT Free to try with your Science Catalogs account.

Abstract

Objective To compare metabolic outcomes in virologically suppressed PLWH switching from EFV/TDF/3TC to either B/F/TAF or DTG/3TC. Methods In this retrospective real-world study of 326 patients, weight, lipid (TG, TC), glucose (GLU), and uric acid (SUA) changes were assessed over 24 months. Generalized linear mixed models and logistic regression identified factors associated with metabolic trends and clinically significant weight gain (>5%). Results The B/F/TAF and DTG/3TC groups showed no significant between-group differences in the longitudinal trends of TG, TC, GLU, or SUA, the incidence of metabolic abnormalities, or the risk of >5% weight gain (all P > 0.05). Within-group analyses indicated the B/F/TAF regimen increased TC ( P < 0.001) and decreased GLU ( P = 0.013), whereas DTG/3TC did not significantly alter TG, TC, or GLU levels. Both regimens increased SUA and body weight (B/F/TAF: +2.5 kg; DTG/3TC: +3.3 kg; both P < 0.001). Modifiable risk factors were associated with metabolic outcomes: smoking with increased TG and TC; hypertension and BMI≥25 kg/m 2 with increased TC, GLU, and SUA; age≥50 years with increased GLU and SUA; and regular alcohol consumption with >5% weight gain (adjusted OR = 1.92, P = 0.008). These findings remained consistent in participants with hypertension. Conclusion In virologically suppressed PLWH, switching to B/F/TAF or DTG/3TC provides comparable metabolic safety profiles. Clinical management should prioritize individualized regimen selection alongside proactive management of traditional metabolic risk factors.

Fields of Study & Subjects

HIV-related health complications and treatments HIV/AIDS drug development and treatment HIV/AIDS Research and Interventions

Publication details

Journal / source
Frontiers in Pharmacology
Volume
17
Pages
1753242–1753242
Publication date
31 March 2026
Language
EN